AVALO THERAPEUTICS, INC. Payments for Repurchase of Initial Public Offering
AVALO THERAPEUTICS, INC. (AVTX) reported Payments for Repurchase of Initial Public Offering of $26.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRepurchaseOfInitialPublicOffering · last filed 2026-08-06
- 2026-06-30: Payments for Repurchase of Initial Public Offering 6 month $26.40M.
- 2025-06-30: Payments for Repurchase of Initial Public Offering 6 month $0.00.
| Period end | Payments for Repurchase of Initial Public Offering 6 month |
|---|---|
| 2026-06-30 | $26.40M 10-Q · filed 2026-08-06 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |